SCHEMBL14958112

SCHEMBL14958112

CCOC(C/N=C/c1cccc(OC)c1OC)OCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.47
KDM4E B2RXH2 2/20 0.47
LMNA P02545 2/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.46
CA12 O43570 1/20 0.44
NFE2L2 Q16236 6/20 0.43
GAA P10253 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
BCHE P06276 1/20 0.40
BACE1 P56817 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14958113 1.00 MAPT (0.47) MAPTKDM4ELMNAHPGDHSD17B10
SCHEMBL14837874 0.77 KDM4E (0.35) MAPTKDM4ECA12BCHE
SCHEMBL14837869 0.77 KDM4E (0.35) MAPTKDM4ECA12BCHE
SCHEMBL14834915 0.77 KDM4E (0.52) MAPTKDM4ELMNAHPGDHSD17B10
SCHEMBL14834911 0.77 KDM4E (0.52) MAPTKDM4ELMNAHPGDHSD17B10
SCHEMBL5721534 0.75 CA12 (0.55) MAPTKDM4ELMNAHPGDHSD17B10
SCHEMBL5721539 0.75 CA12 (0.55) MAPTKDM4ELMNAHPGDHSD17B10
SCHEMBL20388942 0.75 ALDH1A1 (0.36) MAPTKDM4ELMNAHPGDCA12
SCHEMBL20379749 0.75 ALDH1A1 (0.36) MAPTKDM4ELMNAHPGDCA12
SCHEMBL20379748 0.75 ALDH1A1 (0.36) MAPTKDM4ELMNAHPGDCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131018-A1 SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS EXONHIT S.A. (FR) 2013-05-23 US disclosed
US-20130131018-A1 SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS EXONHIT S.A. (FR) 2013-05-23 US disclosed
US-20130131018-A1 SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS EXONHIT S.A. (FR) 2013-05-23 US disclosed
WO-2011151423-A1 SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS EXONHIT S.A. (FR) 2011-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131018-A1 SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS TUBB3, TUBB, TUBB1 MAPT 29/4885KDM4E 3218/4885LMNA 1960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.